Impel press release
Witryna25 kwi 2024 · SEATTLE, April 25, 2024 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is changing its name to Impel Pharmaceuticals. Witryna15 lis 2024 · Please refer to the section in this press release titled "Reconciliation of GAAP and Non-GAAP Results" for details. Cash Balance: As of September 30, 2024, …
Impel press release
Did you know?
Witryna11 kwi 2024 · SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, announced today that four Trudhesa ® (dihydroergotamine mesylate) nasal … Witryna2 sie 2024 · Impel Launches Next-Gen Alternative to SWIFT, SEPA on the XDC Network 4. Press Release July 1, 2024. Impel’s services will run on the XDC Network, a top …
Witryna17 mar 2024 · SEATTLE, March 17, 2024 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with... Witryna16 maj 2024 · SEATTLE, May 16, 2024 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today reported financial …
Witryna2 godz. temu · Spherix Global Insights recently released data from their Launch Dynamix™: Trudhesa in Acute Treatment of Migraine (US) deep dive study tracking the launch of Impel's Trudhesa for the acute ... WitrynaThe Impel Platform; Merchandising; Communication; Imaging; Enterprise Developer Cloud; Integrations; Solutions. Dealership Groups; Local Auto Dealers; Specialty …
Witryna30 sie 2024 · Basel, August 30, 2024 — Novartis will present new data from its robust portfolio and pipeline of advanced therapeutic platforms in solid tumors, with more than 55 abstracts from Novartis-sponsored and investigator-initiated trials accepted at the upcoming European Society for Medical Oncology (ESMO) Congress 2024.
Witryna7 wrz 2024 · SEATTLE, Sept. 07, 2024 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that it … dyson dc63 specWitryna2 cze 2024 · SEATTLE, June 02, 2024 (GLOBE NEWSWIRE) -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, announced today that it will … dyson dc62 battery lifeWitryna16 sie 2024 · SEATTLE, August 16, 2024 — Impel NeuroPharma (NASDAQ: IMPL), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS, today reported … cscvf45991Witryna15 lis 2024 · SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today reported financial … cscvf36683csc verviers prime syndicaleWitryna18 sty 2024 · This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform … csc valve meaningWitryna5 maj 2024 · SEATTLE, May 5, 2024 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced an expanded role of Adrian Adams, … dyson dc65 animal pro